Understand the bias, discover the truth in your news. Get Started
Weekly Voice Article Rating

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation | Weekly Voice

  • Bias Rating

    -2% Center

  • Reliability

    25% ReliableLimited

  • Policy Leaning

    -2% Center

  • Politician Portrayal

    N/A

Bias Score Analysis

The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.

Sentiments

Overall Sentiment

28% Positive

  •   Liberal
SentenceSentimentBias
Unlock this feature by upgrading to the Pro plan.

Bias Meter

Extremely
Liberal

Very
Liberal

Moderately
Liberal

Somewhat Liberal

Center

Somewhat Conservative

Moderately
Conservative

Very
Conservative

Extremely
Conservative

-100%
Liberal

100%
Conservative

Bias Meter

Contributing sentiments towards policy:

51% : In particular, our expectations regarding Exl-111 or the transaction described in this press release could be affected by, among other things, the satisfaction of customary closing conditions including regulatory approvals, as well as uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future demand for our products; and other risks and factors referred to in Novartis AG's most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.

Category
Topic
Copy link